Griffon shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 64 to 88.
Griffon shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 64 to 88.
Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...